Advertisement

Pathophysiology and Treatment of Resistant Hypertension: The Role of Aldosterone and Amiloride-Sensitive Sodium Channels

      Summary

      Resistant hypertension is a clinically distinct subgroup of hypertension defined by the failure to achieve blood pressure control on optimal dosing of at least 3 antihypertensive medications of different classes, including a diuretic. The pathophysiology of hypertension can be attributed to aldosterone excess in more than 20% of patients with resistant hypertension. Existing dogma attributes the increase in blood pressure seen with increases in aldosterone to its antinatriuretic effects in the distal nephron. However, emerging research, which has identified and has begun to define the function of amiloride-sensitive sodium channels and mineralocorticoid receptors in the systemic vasculature, challenges impaired natriuresis as the sole cause of aldosterone-mediated resistant hypertension. This review integrates these findings to better define the role of the vasculature and aldosterone in the pathophysiology of resistant hypertension. In addition, a brief guide to the treatment of resistant hypertension is presented.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Nephrology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Goldblatt H.
        • Lynch J.
        • Hanzal R.F.
        • Summerville W.W.
        Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia.
        J Exp Med. 1934; 59: 347-379
        • Basso N.
        • Terragno N.A.
        History about the discovery of the renin-angiotensin system.
        Hypertension. 2001; 38: 1246-1249
        • Montani J.P.
        • Van Vliet B.N.
        Understanding the contribution of Guyton׳s large circulatory model to long-term control of arterial pressure.
        Exp Physiol. 2009; 94: 382-388
        • Osborn J.W.
        • Averina V.A.
        • Fink G.D.
        Current computational models do not reveal the importance of the nervous system in long-term control of arterial pressure.
        Exp Physiol. 2009; 94: 389-396
        • Nguyen Dinh Cat A.
        • Griol-Charhbili V.
        • Loufrani L.
        • Labat C.
        • Benjamin L.
        • Farman N.
        • et al.
        The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure.
        FASEB J. 2010; 24: 2454-2463
        • McCurley A.
        • Pires P.W.
        • Bender S.B.
        • Aronovitz M.
        • Zhao M.J.
        • Metzger D.
        • et al.
        Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors.
        Nat Med. 2012; 18: 1429-1433
        • McCurley A.
        • Jaffe I.Z.
        Mineralocorticoid receptors in vascular function and disease.
        Mol Cell Endocrinol. 2012; 350: 256-265
        • Schiffrin E.L.
        Vascular mineralocorticoid receptors regulate blood pressure effects on myogenic tone and role in aging.
        Circ Res. 2013; 112: 415-417
        • Jeggle P.
        • Callies C.
        • Tarjus A.
        • Fassot C.
        • Fels J.
        • Oberleithner H.
        • et al.
        Epithelial sodium channel stiffens the vascular endothelium in vitro and in Liddle mice.
        Hypertension. 2013; 61: 1053-1059
        • Warnock D.G.
        • Kusche-Vihrog K.
        • Tarjus A.
        • Sheng S.
        • Oberleithner H.
        • Kleyman T.R.
        • et al.
        Blood pressure and amiloride-sensitive sodium channels in vascular and renal cells.
        Nat Rev Nephrol. 2014; 10: 146-157
        • Calhoun D.A.
        • Jones D.
        • Textor S.
        • Goff D.C.
        • Murphy T.P.
        • Toto R.D.
        • et al.
        Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.
        Hypertension. 2008; 51: 1403-1419
        • Sarafidis P.A.
        • Georgianos P.
        • Bakris G.L.
        Resistant hypertension-its identification and epidemiology.
        Nat Rev Nephrol. 2013; 9: 492
        • Pierdomenico S.D.
        • Lapenna D.
        • Bucci A.
        • Di Tommaso R.
        • Di Mascio R.
        • Manente B.M.
        • et al.
        Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension.
        Am J Hypertens. 2005; 18: 1422-1428
        • Salles G.F.
        • Cardoso C.R.
        • Muxfeldt E.S.
        Prognostic influence of office and ambulatory blood pressures in resistant hypertension.
        Arch Intern Med. 2008; 168: 2340-2346
        • Tanner R.M.
        • Calhoun D.A.
        • Bell E.K.
        • Bowling C.B.
        • Gutierrez O.M.
        • Irvin M.R.
        • et al.
        Prevalence of apparent treatment-resistant hypertension among individuals with CKD.
        Clin J Am Soc Nephrol. 2013; 8: 1583-1590
        • Tanner R.M.
        • Calhoun D.A.
        • Bell E.K.
        • Bowling C.B.
        • Gutierrez O.M.
        • Irvin M.R.
        • et al.
        Incident ESRD and treatment-resistant hypertension: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study.
        Am J Kidney Dis. 2014; 63: 781-788
        • Lifton R.P.
        • Gharavi A.G.
        • Geller D.S.
        Molecular mechanisms of human hypertension.
        Cell. 2001; 104: 545-556
        • Guyton A.C.
        • Coleman T.G.
        Long-term regulation of the circulation: interrelationships with body fluid volumes.
        in: Reeve E.B. Guyton A.C. Physical bases of circulatory transport regulation and exchange. Saunders, Philadelphia1967: 179-201
        • Guyton A.C.
        Renal function curve--a key to understanding the pathogenesis of hypertension.
        Hypertension. 1987; 10: 1-6
        • Kimura G.
        • Saito F.
        • Kojima S.
        • Yoshimi H.
        • Abe H.
        • Kawano Y.
        • et al.
        Renal function curve in patients with secondary forms of hypertension.
        Hypertension. 1987; 10: 11-15
        • Curtis J.J.
        • Luke R.G.
        • Dustan H.P.
        • Kashgarian M.
        • Whelchel J.D.
        • Jones P.
        • et al.
        Remission of essential hypertension after renal transplantation.
        N Engl J Med. 1983; 309: 1009-1015
        • Rettig R.
        • Grisk O.
        The kidney as a determinant of genetic hypertension: evidence from renal transplantation studies.
        Hypertension. 2005; 46: 463-468
        • Crowley S.D.
        • Gurley S.B.
        • Oliverio M.I.
        • Pazmino A.K.
        • Griffiths R.
        • Flannery P.J.
        • et al.
        Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system.
        J Clin Invest. 2005; 115: 1092-1099
        • Coffman T.M.
        • Crowley S.D.
        Kidney in hypertension: Guyton redux.
        Hypertension. 2008; 51: 811-816
        • Jain G.
        • Ong S.
        • Warnock D.G.
        Genetic disorders of potassium homeostasis.
        Semin Nephrol. 2013; 33: 300-309
        • Calhoun D.A.
        • Nishizaka M.K.
        • Zaman M.A.
        • Thakkar R.B.
        • Weissmann P.
        Hyperaldosteronism among black and white subjects with resistant hypertension.
        Hypertension. 2002; 40: 892-896
        • Eide I.K.
        • Torjesen P.A.
        • Drolsum A.
        • Babovic A.
        • Lilledahl N.P.
        Low-renin status in therapy-resistant hypertension: a clue to efficient treatment.
        J Hypertens. 2004; 22: 2217-2226
        • Rossier B.C.
        1996 Homer Smith Award Lecture. Cum grano salis: the epithelial sodium channel and the control of blood pressure.
        J Am Soc Nephrol. 1997; 8: 980-992
        • Studer R.A.
        • Person E.
        • Robinson-Rechavi M.
        • Rossier B.C.
        Evolution of the epithelial sodium channel and the sodium pump as limiting factors of aldosterone action on sodium transport.
        Physiol Genomics. 2011; 43: 844-854
        • Rossier B.C.
        • Staub O.
        • Hummler E.
        Genetic dissection of sodium and potassium transport along the aldosterone-sensitive distal nephron: importance in the control of blood pressure and hypertension.
        FEBS Lett. 2013; 587: 1929-1941
        • Park J.B.
        • Schiffrin E.L.
        ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats.
        Hypertension. 2001; 37: 1444-1449
        • Vasan R.S.
        • Evans J.C.
        • Larson M.G.
        • Wilson P.W.
        • Meigs J.B.
        • Rifai N.
        • et al.
        Serum aldosterone and the incidence of hypertension in nonhypertensive persons.
        N Engl J Med. 2004; 351: 33-41
        • Savoia C.
        • Touyz R.M.
        • Amiri F.
        • Schiffrin E.L.
        Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients.
        Hypertension. 2008; 51: 432-439
        • Pratt J.H.
        • Eckert G.J.
        • Newman S.
        • Ambrosius W.T.
        Blood pressure responses to small doses of amiloride and spironolactone in normotensive subjects.
        Hypertension. 2001; 38: 1124-1129
        • Chapman N.
        • Dobson J.
        • Wilson S.
        • Dahlof B.
        • Sever P.S.
        • Wedel H.
        • et al.
        Effect of spironolactone on blood pressure in subjects with resistant hypertension.
        Hypertension. 2007; 49: 839-845
        • Nishizaka M.K.
        • Zaman M.A.
        • Calhoun D.A.
        Efficacy of low-dose spironolactone in subjects with resistant hypertension.
        Am J Hypertens. 2003; 16: 925-930
        • Oxlund C.S.
        • Henriksen J.E.
        • Tarnow L.
        • Schousboe K.
        • Gram J.
        • Jacobsen I.A.
        Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial.
        J Hypertens. 2013; 31: 2094-2102
        • Min L.J.
        • Mogi M.
        • Iwanami J.
        • Li J.M.
        • Sakata A.
        • Fujita T.
        • et al.
        Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence.
        Cardiovasc Res. 2007; 76: 506-516
        • Yamada M.
        • Kushibiki M.
        • Osanai T.
        • Tomita H.
        • Okumura K.
        Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization.
        Cardiovasc Res. 2008; 79: 169-178
        • Batenburg W.W.
        • Jansen P.M.
        • van den Bogaerdt A.J.
        • Danser A.H.
        Angiotensin II-aldosterone interaction in human coronary microarteries involves GPR30, EGFR, and endothelial NO synthase.
        Cardiovasc Res. 2012; 94: 136-143
        • Jaffe I.Z.
        • Mendelsohn M.E.
        Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells.
        Circ Res. 2005; 96: 643-650
        • Di Zhang A.
        • Nguyen Dinh Cat A.
        • Soukaseum C.
        • Escoubet B.
        • Cherfa A.
        • Messaoudi S.
        • et al.
        Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling.
        Hypertension. 2008; 52: 1060-1067
        • Jain G.
        • Campbell R.C.
        • Warnock D.G.
        Mineralocorticoid receptor blockers and chronic kidney disease.
        Clin J Am Soc Nephrol. 2009; 4: 1685-1691
        • Rautureau Y.
        • Paradis P.
        • Schiffrin E.L.
        Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells.
        Steroids. 2011; 76: 834-839
        • [Anonymous]
        The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I.
        JAMA. 1992; 267: 1213-1220
        • [Anonymous]
        Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion.
        Intersalt Cooperative Research Group. BMJ. 1988; 297: 319-328
        • Sacks F.M.
        • Svetkey L.P.
        • Vollmer W.M.
        • Appel L.J.
        • Bray G.A.
        • Harsha D.
        • et al.
        Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group.
        N Engl J Med. 2001; 344: 3-10
        • He F.J.
        • Markandu N.D.
        • Sagnella G.A.
        • MacGregor G.A.
        Importance of the renin system in determining blood pressure fall with salt restriction in black and white hypertensives.
        Hypertension. 1998; 32: 820-824
        • Oliver W.J.
        • Cohen E.L.
        • Neel J.V.
        Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a "no-salt" culture.
        Circulation. 1975; 52: 146-151
        • Nowaczynski W.
        • Oliver W.J.
        • Neel J.V.
        Serum aldosterone and protein-binding variables in Yanomama Indians: a no-salt culture as compared to partially acculturated Guaymi Indians.
        Clin Physiol Biochem. 1985; 3: 289-306
        • Whelton P.K.
        Potassium and blood pressure.
        in: Sica D.A. Black H.R. Hypertension primer. 4th ed. American Heart Association: Council on High Blood Pressure Research, Dallas, TX2008: 304-306
        • Cook N.R.
        • Obarzanek E.
        • Cutler J.A.
        • Buring J.E.
        • Rexrode K.M.
        • Kumanyika S.K.
        • et al.
        Joint effects of sodium and potassium intake on subsequent cardiovascular disease: the Trials of Hypertension Prevention follow-up study.
        Arch Intern Med. 2009; 169: 32-40
        • Adrogue H.J.
        • Madias N.E.
        Sodium surfeit and potassium deficit: keys to the pathogenesis of hypertension.
        J Am Soc Hypertens. 2014; 8: 203-213
        • Oberleithner H.
        Aldosterone makes human endothelium stiff and vulnerable.
        Kidney Int. 2005; 67: 1680-1682
        • Kusche-Vihrog K.
        • Jeggle P.
        • Oberleithner H.
        The role of ENaC in vascular endothelium.
        Pflugers Arch. 2014; 466: 851-859
        • Kusche-Vihrog K.
        • Sobczak K.
        • Bangel N.
        • Wilhelmi M.
        • Nechyporuk-Zloy V.
        • Schwab A.
        • et al.
        Aldosterone and amiloride alter ENaC abundance in vascular endothelium.
        Pflugers Arch. 2008; 455: 849-857
        • Kusche-Vihrog K.
        • Callies C.
        • Fels J.
        • Oberleithner H.
        The epithelial sodium channel (ENaC): mediator of the aldosterone response in the vascular endothelium?.
        Steroids. 2010; 75: 544-549
        • Druppel V.
        • Kusche-Vihrog K.
        • Grossmann C.
        • Gekle M.
        • Kasprzak B.
        • Brand E.
        • et al.
        Long-term application of the aldosterone antagonist spironolactone prevents stiff endothelial cell syndrome.
        FASEB J. 2013; 27: 3652-3659
        • Perez F.R.
        • Venegas F.
        • Gonzalez M.
        • Andres S.
        • Vallejos C.
        • Riquelme G.
        • et al.
        Endothelial epithelial sodium channel inhibition activates endothelial nitric oxide synthase via phosphoinositide 3-kinase/Akt in small-diameter mesenteric arteries.
        Hypertension. 2009; 53: 1000-1007
        • Wang S.
        • Meng F.
        • Mohan S.
        • Champaneri B.
        • Gu Y.
        Functional ENaC channels expressed in endothelial cells: a new candidate for mediating shear force.
        Microcirculation. 2009; 16: 276-287
        • Chatzizisis Y.S.
        • Coskun A.U.
        • Jonas M.
        • Edelman E.R.
        • Feldman C.L.
        • Stone P.H.
        Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior.
        J Am Coll Cardiol. 2007; 49: 2379-2393
        • Collier T.J.
        • Pocock S.J.
        • McMurray J.J.
        • Zannad F.
        • Krum H.
        • van Veldhuisen D.J.
        • et al.
        The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial.
        Eur Heart J. 2013; 34: 2823-2829
        • Krum H.
        • Shi H.
        • Pitt B.
        • McMurray J.
        • Swedberg K.
        • van Veldhuisen D.J.
        • et al.
        Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
        Circ Heart Fail. 2013; 6: 711-718
        • Pitt B.
        • Zannad F.
        • Remme W.J.
        • Cody R.
        • Castaigne A.
        • Perez A.
        • et al.
        The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
        N Engl J Med. 1999; 341: 709-717
        • Pitt B.
        • Remme W.
        • Zannad F.
        • Neaton J.
        • Martinez F.
        • Roniker B.
        • et al.
        Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
        N Engl J Med. 2003; 348: 1309-1321
        • Zannad F.
        • McMurray J.J.
        • Krum H.
        • van Veldhuisen D.J.
        • Swedberg K.
        • Shi H.
        • et al.
        Eplerenone in patients with systolic heart failure and mild symptoms.
        N Engl J Med. 2011; 364: 11-21
        • Anonymous
        Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
        JAMA. 2002; 288: 2981-2997
        • Egan B.M.
        • Zhao Y.
        • Axon R.N.
        • Brzezinski W.A.
        Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008.
        Circulation. 2011; 124: 1046-1058
        • Jamerson K.
        • Weber M.A.
        • Bakris G.L.
        • Dahlof B.
        • Pitt B.
        • Shi V.
        • et al.
        Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
        N Engl J Med. 2008; 359: 2417-2428
        • Krause T.
        • Lovibond K.
        • Caulfield M.
        • McCormack T.
        • Williams B.
        Management of hypertension: summary of NICE guidance.
        Br Med J. 2011; 343: d4891
        • Mancia G.
        • Fagard R.
        • Narkiewicz K.
        • Redon J.
        • Zanchetti A.
        • Bohm M.
        • et al.
        2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
        Eur Heart J. 2013; 34: 2159-2219
        • James P.A.
        • Oparil S.
        • Carter B.L.
        • Cushman W.C.
        • Dennison-Himmelfarb C.
        • Handler J.
        • et al.
        2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).
        JAMA. 2014; 11: 507-520
        • Shimkets R.A.
        • Warnock D.G.
        • Bositis C.M.
        • Nelson-Williams C.
        • Hansson J.H.
        • Schambelan M.
        • et al.
        Liddle׳s syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel.
        Cell. 1994; 79: 407-414
        • Wilson F.H.
        • Disse-Nicodeme S.
        • Choate K.A.
        • Ishikawa K.
        • Nelson-Williams C.
        • Desitter I.
        • et al.
        Human hypertension caused by mutations in WNK kinases.
        Science. 2001; 293: 1107-1112
        • Warnock D.G.
        Aldosterone-related genetic effects in hypertension.
        Curr Hypertens Rep. 2000; 2: 295-301
        • Pimenta E.
        • Gaddam K.K.
        • Oparil S.
        • Aban I.
        • Husain S.
        • Dell׳Italia L.J.
        • et al.
        Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial.
        Hypertension. 2009; 54: 475-481
        • Bernstein A.M.
        • Willett W.C.
        Trends in 24-h urinary sodium excretion in the United States, 1957-2003: a systematic review.
        Am J Clin Nutr. 2010; 92: 1172-1180
        • Collste P.
        • Garle M.
        • Rawlins M.D.
        • Sjoqvist F.
        Interindividual differences in chlorthalidone concentration in plasma and red cells of man after single and multiple doses.
        Eur J Clin Pharmacol. 1976; 9: 319-325
        • Riess W.
        • Dubach U.C.
        • Burckhardt D.
        • Theobald W.
        • Vuillard P.
        • Zimmerli M.
        Pharmacokinetic studies with chlorthalidone (Hygroton) in man.
        Eur J Clin Pharmacol. 1977; 12: 375-382
        • Carter B.L.
        • Ernst M.E.
        • Cohen J.D.
        Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability.
        Hypertension. 2004; 43: 4-9
        • Ernst M.E.
        • Carter B.L.
        • Goerdt C.J.
        • Steffensmeier J.J.
        • Phillips B.B.
        • Zimmerman M.B.
        • et al.
        Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.
        Hypertension. 2006; 47: 352-358
        • Kim G.H.
        • Masilamani S.
        • Turner R.
        • Mitchell C.
        • Wade J.B.
        • Knepper M.A.
        The thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein.
        Proc Natl Acad Sci U S A. 1998; 95: 14552-14557
        • Raheja P.
        • Price A.
        • Wang Z.
        • Arbique D.
        • Adams-Huet B.
        • Auchus R.J.
        • et al.
        Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients.
        Hypertension. 2012; 60: 319-325
        • Ori Y.
        • Chagnac A.
        • Korzets A.
        • Zingerman B.
        • Herman-Edelstein M.
        • Bergman M.
        • et al.
        Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone.
        Nephrol Dial Transplant. 2013; 28: 1787-1793
        • Funder J.W.
        Primary aldosteronism and low-renin hypertension: a continuum?.
        Nephrol Dial Transplant. 2013; 28: 1625-1627
        • Warnock D.G.
        The amiloride-sensitive endothelial sodium channel and vascular tone.
        Hypertension. 2013; 61: 952-954
        • Barauna V.G.
        • Mantuan P.R.
        • Magalhaes F.C.
        • Campos L.C.
        • Krieger J.E.
        AT1 receptor blocker potentiates shear-stress induced nitric oxide production via modulation of eNOS phosphorylation of residues Thr(495) and Ser(1177.).
        Biochem Biophys Res Commun. 2013; 441: 713-719